GH Research Announces Primary Endpoint Met in Two Phase 2a Poc Trials With GH001 and Completion of All FDA Requests to Address Ind Hold With No Findings of Respiratory Toxicity in Non-Rodents

THOMSON REUTERS
10 Jan

GH Research Announces Primary Endpoint Met in Two Phase 2a Poc Trials With GH001 and Completion of All FDA Requests to Address Ind Hold With No Findings of Respiratory Toxicity in Non-Rodents

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10